0001437749-20-023003.txt : 20201106
0001437749-20-023003.hdr.sgml : 20201106
20201106161056
ACCESSION NUMBER: 0001437749-20-023003
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201105
FILED AS OF DATE: 20201106
DATE AS OF CHANGE: 20201106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hanna John Walter JR
CENTRAL INDEX KEY: 0001781127
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36156
FILM NUMBER: 201294519
MAIL ADDRESS:
STREET 1: 6000 SHORELINE COURT
STREET 2: SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERACYTE, INC.
CENTRAL INDEX KEY: 0001384101
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 205455398
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6000 SHORELINE COURT, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 243-6300
MAIL ADDRESS:
STREET 1: 6000 SHORELINE COURT, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: CALDEROME INC
DATE OF NAME CHANGE: 20061219
4
1
rdgdoc.xml
FORM 4
X0306
4
2020-11-05
0001384101
VERACYTE, INC.
VCYT
0001781127
Hanna John Walter JR
6000 SHORELINE COURT
SUITE 300
SOUTH SAN FRANCISCO
CA
94080
1
Chief Commercial Officer
Common Stock
2020-11-05
4
M
0
3125
9.05
A
77434
D
Common Stock
2020-11-05
4
M
0
3281
5.98
A
80715
D
Common Stock
2020-11-05
4
S
0
3613
39.9962
D
77102
D
Common Stock
2020-11-05
4
S
0
2660
41.5594
D
74442
D
Common Stock
2020-11-05
4
S
0
133
42.0801
D
74309
D
Stock Option (right to buy)
9.05
2020-11-05
4
M
0
3125
0
D
2027-03-02
Common Stock
3125
7292
D
Stock Option (right to buy)
5.98
2020-11-05
4
M
0
3281
0
D
2028-03-01
Common Stock
3281
20782
D
The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 11, 2020.
Represents weighted average sales price. Sale prices for the transactions range from $39.95 to $40.78. Detailed information regarding the number of shares sold at each separate price will be provided to the
SEC, the issuer or a shareholder upon request.
Represents weighted average sales price. Sale prices for the transactions range from $41.01 to $42.01. Detailed information regarding the number of shares sold at each separate price will be provided to the
SEC, the issuer or a shareholder upon request.
Represents weighted average sales price. Sale prices for the transactions range from $42.05 to $42.13. Detailed information regarding the number of shares sold at each separate price will be provided to the
SEC, the issuer or a shareholder upon request.
The option became exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
The option became exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
/s/ Keith Kennedy, as Attorney-in-fact
2020-11-06